$26.31
1.566.3%
Last update: Nov 9, 4:46 PM
UroGen Pharma Ltd
URGNNASDAQ
UroGen Pharma rose 13.7% from $23.13 to $26.31, ahead of the S&P 500's +10.5%. Its worst day was Nov 4 (−16.5%), and its low came Mar 30 at $17.00.
Nov 10, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
UroGen Pharma shares fell 15.5%, while the S&P 500 rose 0.1%.
−15.5% · S&P 500 +0.1%
EPS of $-0.54 beat the $-0.57 estimate on $37.8M revenue (est. $38.2M).
−12.4% · S&P 500 +0.1%
Story events cover the past 12 months · Times ET
UroGen Pharma closed at its lowest level of the year, 26.5% below where the year started.
−1.0% · S&P 500 −0.3%
UroGen Pharma shares rose 10.6%, while the S&P 500 fell 0.2%.
+10.6% · S&P 500 −0.2%
EPS of $-0.47 beat the $-0.50 estimate on $51.0M revenue (est. $44.6M).
+10.2% · S&P 500 +1.4%
EPS of $-0.28 beat the $-0.31 estimate on $72.5M revenue (est. $62.1M).
+16.3%, the year's best day · S&P 500 −0.2%
UroGen Pharma closed at its highest level of the year, 117.4% above where the year started.
+2.8% · S&P 500 +0.2%
EPS of $-0.03 missed the $0.09 estimate on $89.0M revenue (est. $89.3M).
−16.5%, the year's worst day · S&P 500 +1.7%
Where it ended: a close of $26.31 on Nov 9, 2026. Up next: Q4 2026 earnings on Mar 1, 2027 (EPS est. $0.43, revenue est. $106.5M).
Nothing in the past 12 months.
All URGN dividend historyReplay the year: the line draws itself and stops at each of the 8 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for URGN and SPY from Benzinga historical bars. Not investment advice.
